Author: Avalon Health Economics LLC

Recent healthcare reforms in the U.S. and abroad have emphasized the value of meaningful and effective preventative care and health promotion. Corporations are taking note, and, as a result, there has been a significant rise in the number of corporate wellness programs popping up. Under recent healthcare legislation in the U.S., there are tax incentives...

Avalon Health Economics will be attending Nordic Life Science Days 2014, Stockholm, Sweden, September 7-9. Avalon will present “Establishing the Value of New Drugs, Devices & Diagnostics” (See Presentation). The NLSD is the largest life sciences meeting held in the Nordic region, and will include representatives from pharmaceutical companies, medical device makers, diagnostics companies, and...

1. What is an E-Cig? The “e-cig” is an electronic cigarette that is used to simulate the experience of smoking that has a cartridge with a heater that vaporizes liquid nicotine instead of burning tobacco. Having become a seemingly overnight sensation, governments in both Europe and the United States are struggling with how to regulate...

Noemi Kiss is a Senior Health Economist with Avalon. She recently earned her MSc in Health Economics from the University of York (United Kingdom). Prior to York, Ms. Kiss was a Health Economist at Oxford Outcomes, Ltd (and Oxford’s parent company ICON plc), from 2010-13. Click here to read her biosketch. In addition to her...

James Robinson joins Avalon Health Economics as a Director. Jamie is the Leonard D. Schaeffer Professor of Health Economics and Director of the Berkeley Center for Health Technology (BCHT) at the University of California at Berkeley. In addition to his role as Director at Avalon Health Economics, his professional activities include his roles as Senior...

Click here to view the presentation

The high cost of adverse events has been estimated to be at least US$177 billion per year in the U.S., and prescription drugs overall have efficacy only approximately 50% of the time, representing a potential waste of approximately $350 billion of the worldwide $700 billion or more drug spending (Miller et al., 2011). The wide...

The Organic and natural food industry has boomed in the last few decades, moving from a small niche market to a $30 billion dollar industry. Across the United States, people are growing more concerned by the possibility that their food choices could negatively affect their health and are responding by buying more products with labels...

Avalon at ISPOR: John Schneider and Cara Scheibling will be attending the annual meeting of the International Society of Pharmacoeconomics and Outcomes Research in Montreal next week, June 1 through June 4. The title of this year’s meeting is “Examining the Role of Big Data in Health Care Decision Making.” If you’d like to meet,...

Avalon will be attending and presenting at the 6th Annual EuroMedtech conference in Linz, Austria, May 7-8. The topic will be on economic evaluation of devices and diagnostics through the product lifecycle. Economic evaluations of new devices and diagnostics should begin early, and should be adjusted and revised throughout the product lifecycle as better data...